Galecto
Yahoo Finance • 2 months ago
Galecto Announces Pricing of $275 Million Underwritten Public Offering
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pri... Full story
Yahoo Finance • 4 months ago
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the... Full story
Yahoo Finance • 5 months ago
Galecto Reports Third Quarter 2025 Operating and Financial Results
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial re... Full story
Yahoo Finance • 8 months ago
Galecto GAAP EPS of -$2.60
* Galecto press release [https://seekingalpha.com/pr/20190193-galecto-reports-second-quarter-2025-operating-and-financial-results] (NASDAQ:GLTO [https://seekingalpha.com/symbol/GLTO]): Q2 GAAP EPS of -$2.60. * Cash and cash equivalents... Full story
Yahoo Finance • last year
Galecto Reports Full-Year 2024 Financial Results
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on... Full story
Yahoo Finance • last year
Galecto to Participate in Upcoming Investor Conferences
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company manageme... Full story
Yahoo Finance • 2 years ago
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new and encouraging clin... Full story
Yahoo Finance • 3 years ago
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its... Full story
Yahoo Finance • 3 years ago
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced t... Full story
Yahoo Finance • 3 years ago
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto Set to Join Russell Microcap® Index
BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced t... Full story
Yahoo Finance • 3 years ago
Galecto to Present Poster at Upcoming ATS 2023 International Conference
Galecto, Inc. BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today... Full story
Yahoo Finance • 3 years ago
Galecto Reports First Quarter Operating and Financial Results
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto to Present Two Posters at AACR Annual Meeting 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announce... Full story
Yahoo Finance • 3 years ago
Galecto to Participate in SVB Securities Global Biopharma Conference
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto Reports Third Quarter Operating and Financial Results
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
Yahoo Finance • 3 years ago
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseases Findings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET B... Full story
Yahoo Finance • 3 years ago
Galecto to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced... Full story
